Français Japonais Chinois Allemand Néerlandais Espagnol Portugais

    News

    Success story: Amaris Lille set to expand

    Switzerland-based Amaris opened an office in Hauts-de-France in late 2015. Ranked among Europe’s leading independent consulting groups, the company is growing exponentially.

    Lille shortlisted as World Design Capital 2020

    Greater Lille and Sydney are the finalists for the biennial title, awarded by the World Design Organization.

    All news

    GSK to produce two new vaccines at Saint-Amand-les-Eaux site

    21 Sep 2016 | Front page, Health Nutrition, Investment

    For years GSK’s plant in Northern France has worked to raise its profile as one of the pharmaceutical group’s strategic assets. Mission accomplished: two new vaccines will soon be rolling off its production lines, spearheading a drive to conquer the US market by 2018.

    Two new vaccines to be produced at GSK’s Saint-Amand-les-Eaux plant

    Plant in Northern France plays key strategic role

    Since 2015, GlaxoSmithKline (GSK) has invested over €13 million to upgrade production lines and ramp up output at its Saint-Amand-les-Eaux facility, as part of the group’s global strategy. Now Saint-Amand has been selected from among GSK’s 18 sites worldwide to produce new vaccines for shingles and malaria. 

    “This new project show that we’ve become a pacesetter within GSK Group,” says Manufacturing Site Director Géraldine Vetterhoeffer, who has just been named Vice-President Quality for GSK Worldwide.

    The investments point to a bright future for the plant, which is set on conquering the American market by 2018.

    Made in France, exported worldwide

    Nearly 40% of the world’s children are treated with a vaccine made by GSK—an achievement that Ms. Vetterhoeffer readily points out. “My greatest source of pride is that our products have such a powerful impact around the world,” she says. 

    GSK currently exports 70% of the products it makes in France.

    Major investment 

    GSK has operated in Saint-Amand-les-Eaux since 2011, putting a total of €600 million into the plant. That’s the largest industrial investment made by a foreign pharmaceutical company in France over the past 20 years, and it has had huge economic implications for Northern France: the site currently has 800 employees, and sales are expected to rise 20% to 30% in the future. 

    Source: Usine Nouvelle / La Voix du Nord 

    Back to news